Seragon

Seragon is a company focused on developing drugs for hormone-dependent cancers, with a mission to drive cutting-edge scientific innovation in medicine and biotechnology. We develop new solutions to address global health challenges and unlock lifelong value for human and animal health. Seragon optimizes human health and longevity worldwide through advanced biomedical design approaches. We are leading the next exciting phase of medical advancements, with significant discoveries in genomic sequencing and diagnostic research globally. Seragon's orally active Selective Estrogen Receptor Degraders (SERDs) represent a potential new approach for treating progressive metastatic breast cancer, which may circumvent resistance to hormonal therapies. SERDs are estrogen receptor antagonists that also induce conformational changes, leading to receptor degradation.